Clinical Trials

Status
Published

Recently Activated

SHOW MORE

Active Filters

    Open
    Phase
    III
    SWOG Clinical Trial Number
    CTSU/NRG-BR007

    A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer

    Status Notes
    CTSU/NRG-BR007 has been endorsed and activated by SWOG, effective 6/15/2021. CTSU/NRG-BR007 was activated by NRG Oncology, effective 6/7/21.
    Research Committee(s)
    Breast Cancer
    Activated
    06-07-2021
    ClinicalTrials.gov Registry Number
    04852887
    Open
    Phase
    II
    SWOG Clinical Trial Number
    CTSU/EA2201

    A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma

    Status Notes
    May Thet Cho, MD SWOG Champion
    Research Committee(s)
    Gastrointestinal Cancer
    Activated
    05-13-2021
    ClinicalTrials.gov Registry Number
    NCT04751370
    Open
    Phase
    III
    SWOG Clinical Trial Number
    CTSU/A031901

    Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial

    Status Notes
    SWOG is participating in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
    Research Committee(s)
    Genitourinary Cancer
    Activated
    05-01-2021
    ClinicalTrials.gov Registry Number
    NCT04637594
    Open
    Phase
    II
    SWOG Clinical Trial Number
    CTSU/EA8185

    Phase II Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)

    Status Notes
    SWOG is participating in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
    Research Committee(s)
    Genitourinary Cancer
    Activated
    05-01-2021
    ClinicalTrials.gov Registry Number
    NCT04216290
    Open
    Phase
    II
    SWOG Clinical Trial Number
    CTSU/EA2192
    Open
    Phase
    II
    Accrual
    14%
    SWOG Clinical Trial Number
    S1900E

    A PHASE II STUDY OF AMG 510 IN PATIENTS WITH PREVIOUSLY TREATED STAGE IV OR RECURRENT KRAS G12C MUTATED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (ECOG-ACRIN LUNG-MAP SUB-STUDY)

    Status Notes
    S1900E will open to accrual April 2, 2021, effective 12:00 pm PST.

    This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
    Research Committee(s)
    LungMAP
    Lung Cancer
    Activated
    04-02-2021